Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ursula A Matulonis

Showing results (21-30 of 236) with videos related to

Pageof 24
Sort By:
Expert Review of Anticancer Therapy|July 17, 2023
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancerRebecca L Porter, Ursula A Matulonis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2018
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative JourneyPanagiotis A Konstantinopoulos, Ursula A Matulonis
Cancer|September 17, 2014
POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testingPanagiotis A Konstantinopoulos, Ursula A Matulonis
The New England Journal of Medicine|February 23, 2017
Niraparib in Recurrent Ovarian CancerMansoor R Mirza, Ursula A Matulonis
Cancers|July 30, 2020
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination TherapiesElizabeth K Lee, Ursula A Matulonis
The Lancet. Oncology|June 28, 2015
Bevacizumab in newly diagnosed ovarian cancerJoyce F Liu, Ursula A Matulonis
Expert Opinion on Emerging Drugs|June 23, 2020
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitorsElizabeth K Lee, Ursula A Matulonis
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Chemotherapy hypersensitivity reactions in ovarian cancerMatthieu Picard, Ursula A Matulonis, Mariana Castells
Gynecologic Oncology|December 15, 2015
Genomic testing and precision medicine--What does this mean for gynecologic oncology?Joyce Liu, Panagiotis A Konstantinopoulos, Ursula A Matulonis
Expert Opinion on Biological Therapy|March 11, 2026
What does the future hold for antibody-drug conjugate therapies in ovarian cancer?Page C Widick, Ursula A Matulonis, Meghan Shea
Pageof 24

Showing results (21-30 of 236) with videos related to

Sort By:
Pageof 24
Expert Review of Anticancer Therapy|July 17, 2023
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancerRebecca L Porter, Ursula A Matulonis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2018
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative JourneyPanagiotis A Konstantinopoulos, Ursula A Matulonis
Cancer|September 17, 2014
POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testingPanagiotis A Konstantinopoulos, Ursula A Matulonis
The New England Journal of Medicine|February 23, 2017
Niraparib in Recurrent Ovarian CancerMansoor R Mirza, Ursula A Matulonis
Cancers|July 30, 2020
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination TherapiesElizabeth K Lee, Ursula A Matulonis
The Lancet. Oncology|June 28, 2015
Bevacizumab in newly diagnosed ovarian cancerJoyce F Liu, Ursula A Matulonis
Expert Opinion on Emerging Drugs|June 23, 2020
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitorsElizabeth K Lee, Ursula A Matulonis
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Chemotherapy hypersensitivity reactions in ovarian cancerMatthieu Picard, Ursula A Matulonis, Mariana Castells
Gynecologic Oncology|December 15, 2015
Genomic testing and precision medicine--What does this mean for gynecologic oncology?Joyce Liu, Panagiotis A Konstantinopoulos, Ursula A Matulonis
Expert Opinion on Biological Therapy|March 11, 2026
What does the future hold for antibody-drug conjugate therapies in ovarian cancer?Page C Widick, Ursula A Matulonis, Meghan Shea
Pageof 24